GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyell Immunopharma Inc (NAS:LYEL) » Definitions » Tax Rate %

Lyell Immunopharma (Lyell Immunopharma) Tax Rate % : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lyell Immunopharma Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Lyell Immunopharma's Tax Expense for the three months ended in Dec. 2023 was $0.00 Mil. Lyell Immunopharma's Pre-Tax Income for the three months ended in Dec. 2023 was $-52.93 Mil. Therefore, Lyell Immunopharma's Tax Rate % for the quarter that ended in Dec. 2023 was 0.00%.


Lyell Immunopharma Tax Rate % Historical Data

The historical data trend for Lyell Immunopharma's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyell Immunopharma Tax Rate % Chart

Lyell Immunopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Rate %
- - - - -

Lyell Immunopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lyell Immunopharma Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Lyell Immunopharma's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2023 )/Pre-Tax Income (A: Dec. 2023 )
=0/-234.632
=0.00 %

Lyell Immunopharma's Tax Rate % for the quarter that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2023 )/Pre-Tax Income (Q: Dec. 2023 )
=0/-52.93
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyell Immunopharma Tax Rate % Related Terms

Thank you for viewing the detailed overview of Lyell Immunopharma's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyell Immunopharma (Lyell Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).
Executives
Richard Klausner director, officer: Executive Chairman 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Matthew Lang officer: Chief Business Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rahsaan Thompson officer: Chief Legal Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Tina M. Albertson officer: Chief Medical Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Gary K. Lee officer: Chief Scientific Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Elizabeth Homans director, officer: Chief Executive Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Stephen J. Hill officer: Chief Technical Ops. Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Charles W. Newton officer: Chief Financial Officer 46 FREDRICK AVENUE, ATHERTON CA 94027
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
William Jl Rieflin director NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Arch Venture Partners Ix, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631